Ann: Appendix 4C and Quarterly Update, page-57

PharmAust SWOTAnalysis

It is a worthwhile exercise to review ones investments from time to time. I thought I would do a basic SWOT analysis to reassure myself that I am invested for the right reasons.

The following is merely my own non-scientific observations of how PAA is generally situated at the moment.

Strengths

· Monepantel has demonstrated meaningful results in all testing to date and has a strong safety profile

· There are multiple shots at goal – Covid, K9 Lymphoma, Human Cancers, MND

· Profitable In-house laboratory – Epichem

· Knowledgeable and experienced scientific leadership

· Financial prudence

· IP protections

· Tightly held Share Register

Weaknesses

· Small team

· Marketing and promotion under par

· Failure to cement Elanco option

Opportunities

· Huge addressable markets

· Breakthrough therapeutics – potential Government funding

· Potential collaborators and/or partnerships

· Potential takeover target

Threats

· Failure to achieve required results in Covid testing would erode share price and confidence

· $$$ Big pharma may not like their lucrative vaccine revenue streams disrupted

· Emerging competitors may grab limelight

My estimation is that the strengths and opportunities outweigh the weaknesses and threats.

This is a general overview from my perspective only. I’m renowned for sometimes missing the obvious so if I’ve overlooked anything, as always - do your own research…

GLTAH, Thrifty